VANGUARD ASSET MANAGEMENT, Ltd
Position in DNLI — Denali Therapeutics Inc.
CIK 1680208
London, EC4N 8AF, X0
Position in DNLI
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$3,630,455
+$1,225,790 QoQ
Shares Held
141,153
+12.7% QoQ
Ownership
0.088%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#76
of 290 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in DNLI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026VANGUARD ASSET MANAGEMENT, Ltd holds $986,738,712 across 154 Biotechnology names. DNLI ranks #39 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
494,186 | $245,477,011 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
197,770 | $123,317,505 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
257,710 | $77,578,441 | |
| 4 | RPRX |
Royalty Pharma plc
|
932,544 | $52,287,742 | |
| 5 | INSM |
INSMED Inc
|
416,108 | $44,365,434 | |
| 6 | INCY |
Incyte Corp
|
335,081 | $37,984,782 | |
| 7 | MRNA |
Moderna, Inc.
|
330,089 | $23,116,132 | |
| 8 | RVMD |
Revolution Medicines, Inc.
|
92,056 | $17,240,247 |
All Filings in DNLI
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,630,455 | 141,153 | Shares | Defined | 2026-08-13 | |
| 2026-03-31 | $2,404,665 | 125,243 | Shares | Defined | 2026-05-08 | |
| No filing history on record for this holder in this stock. | ||||||